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ABSTRACT
OBJECTIVES This meta-analysis evaluates assessment of pulmonary arterial hypertension (PAH), with a focus on
clinical worsening and mortality.
BACKGROUND Cardiacmagnetic resonance (CMR) has prognostic value in the assessment of patients with PAH. However,
there are limited data on the prediction of clinical worsening, an important composite endpoint used in PAH therapy trials.
METHODS The Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, and Web of Science databases were
searched in May 2020. All CMR studies assessing clinical worsening and the prognosis of patients with PAH were
included. Pooled hazard ratios of univariate regression analyses for CMR measurements, for prediction of clinical wors-
ening and mortality, were calculated.
RESULTS Twenty-two studies with 1,938 participants were included in themeta-analysis. There were 18 clinical worsening
events and 8 deaths per 100 patient-years. The pooled hazard ratios show that every 1% decrease in right ventricular (RV)
ejection fraction is associated with a 4.9% increase in the risk of clinical worsening over 22 months of follow-up and a 2.2%
increase in the risk of death over 54 months. For every 1 ml/m2 increase in RV end-systolic volume index or RV end-diastolic
volume index, the risk of clinical worsening increases by 1.3% and 0.7%, respectively, and the risk of mortality increases by
0.9% and 1%. Every 1 ml/m2 decrease in left ventricular end-systolic volume index or left ventricular end-diastolic volume
index increased the risk of death by 2.1% and 2.3%. Left ventricular parameters were not associated with clinical worsening.
CONCLUSIONS This review confirms CMR as a powerful prognostic marker in PAH in a large cohort of patients. In
addition to confirming previous observations that RV function and RV and left ventricular volumes predict mortality, RV
function and volumes also predict clinical worsening. This study provides a strong rationale for considering CMR as a
clinically relevant endpoint for trials of PAH therapies. (J Am Coll Cardiol Img 2020;-:-–-) © 2020 The Authors.
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P
ulmonary arterial hypertension (PAH)
is characterized by remodeling of the
distal pulmonary arteries, leading to
an increase in pulmonary vasculature resis-
tance, reduced compliance, and elevated pul-
monary artery pressure (1–3). Untreated, PAH
has high morbidity and mortality that are
closely linked to right ventricular (RV)
dysfunction (2). A new diagnosis of PAH in-
creases the risk of death at 1 year fivefold
(4). However, over the last 20 years, treat-
ment advancements have led to an increase
in median survival from 3 to 7 years (4–6),
although development of new therapies is
needed.
Recently, clinical studies of PAH therapies
have moved from assessing exercise capacity
and pulmonary hemodynamics to using
composite endpoints. One such approach
uses the time to clinical worsening. Clinical
worsening events include hospitalization,
disease progression, and unsatisfactory long-
term clinical response, in addition to mor-
tality (7). However, given the large number of
patients required and the expense of con-
ducting such event-driven studies, cardiac
magnetic resonance (CMR) has recently been
explored as a primary endpoint to evaluate PAH
therapies (8).
CMR is the gold standard method of measuring RV
function, volumes, and mass, and it is an established
prognostic and therapy response tool (1,9,10). In 2015,
a meta-analysis assessed the prognostic value of CMR
measurements in 5 studies with 332 participants (9);
however, no data were reported on clinical wors-
ening. Since then, multiple new studies assessing
clinical worsening in addition to mortality have been
published in PAH.
The current meta-analysis also includes unpub-
lished supplemental data on CMR metrics from 16
previously published studies, which allowed us to
provide new data on the utility of CMR to predict
clinical worsening in addition to mortality. The goal
of the current study therefore was to review the evi-
dence for CMR metrics to predict clinical worsening
and mortality in patients with PAH.
METHODS
The review was prospectively registered with The
International Prospective Register of Systematic Re-
views on December 12, 2019 (ID: CRD42019160296).
The Preferred Reporting Items for Systematic reviews
and Meta-Analysis guidelines were followed (11).
Ethical approval was not required for this meta-
analysis because it was based on published litera-
ture and did not recruit patients.
CRITERIA FOR CONSIDERING STUDIES FOR REVIEW.
Studies of all forms of PAH (including idiopathic PAH
[IPAH], heritable, drug- and toxin-induced PAH, and
PAH associated with connective tissue disease [CTD];
congenital heart disease; HIV infection; and portal
hypertension) were considered for inclusion in the
meta-analysis. For studies including patients with
different forms of pulmonary hypertension (PH), data
from these studies were incorporated only if the PAH
cohort was separately described or the PAH partici-
pants formed at least one-half of the study popula-
tion. To obtain additional data on patients with PAH,
which may have been collected but not published,
authors were contacted and supplemental data
requested. Case reports or small cases series of <10
participants were excluded. Data collected included
any clinically relevant outcomes such as hospitaliza-
tion due to heart failure, disease progression, unsat-
isfactory long-term clinical response, and death. To
allow for analysis, only studies that reported Cox
regression hazard ratios expressed per unit of mea-
surement were included. One study reporting
dichotomized hazard ratios was excluded because
raw hazard ratios could not be obtained after con-
tacting the study author.
SEARCH METHODS FOR IDENTIFICATION OF
STUDIES. The following databases were systemati-
cally searched for relevant studies on May 13, 2020:
Cochrane Central Register of Controlled Trials (Cen-
tral) (Issue 1, May 2020), MEDLINE (ProQuest, 1946 to
May 6, 2020), EMBASE (Ovid, 1974 to 2020 Week 20),
and Web of Science (to May 13, 2020). The search
strategy used is outlined in Supplemental Appendix 1.
The reference lists of all relevant articles identified
during the full-text screening were scrutinized for
relevant studies.
DATA COLLECTION AND ANALYSIS. Details about
the selection of studies, data extraction and man-
agement, and statistical analysis and data synthesis
are provided in Supplemental Appendix 2.
RESULTS
SEARCH RESULTS. Our comprehensive search iden-
tified a total of 22 studies that were included in the
meta-analysis (12–33). The details of the literature
search are presented in the supplemental materials,
including a Preferred Reporting Items for
Systematic Reviews and Meta-Analysis flow diagram
(Supplemental Appendix 3).
ABBR EV I A T I ON S
AND ACRONYMS
CMR = cardiac magnetic
resonance
CTD = connective tissue
disease
IPAH = idiopathic pulmonary
arterial hypertension
LV = left ventricular
LVEDVI = left ventricular end-
diastolic volume index
mPAP = mean pulmonary
artery pressure
PAH = pulmonary arterial
hypertension
PH = pulmonary hypertension
RV = right ventricular
RVEDVI = right ventricular
end-diastolic volume index
RVEF = right ventricular
ejection fraction
RVESVI = right ventricular
end-systolic volume index
RVMI = right ventricular mass
index
VMI = ventricular mass index
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DESCRIPTION OF INCLUDED STUDIES. Study
design. The review includes 14 case series and 8 case-
control studies. Prospective recruitment was per-
formed in 12 studies, and consecutive inclusion was
reported in 10 studies. Apart from Leng et al. (21), all
studies were single tertiary center studies. The
studies were published between 2007 and 2020, with
16 studies including 1,606 participants published
since the previous meta-analysis in 2015. Most
studies (18 studies) had a small sample size of <100
patients, with the largest study by Swift et al. (26)
including 576 participants.
POPULATION. The 22 studies were conducted in 9
different countries and included 2,149 participants. A
total of 1,938 participants were included in the meta-
analysis, of whom 97% had PAH and 3% had other
types of PH. IPAH comprised 51% and CTD-PAH 26%
of the PAH population. Dawes 2018 (31), de Siqueira
2016 (16), and Jose 2019 (30) kindly provided addi-
tional data that allowed identification of patients
with PAH from a mixed PH cohort.
Participants were aged 52  15 years, with a female
predominance (68%) and a pooled average mean
pulmonary artery pressure (mPAP) of 49  15 mm Hg
and RV ejection fraction (RVEF) of 37  14%. Details
of the included studies are presented in Table 1. The
pooled baseline CMR measurements are shown in
Figure 1.
Methodological quality of included studies. One-half of
the studies had a prospective design, consecutive
recruitment of participants, and reported blinding
of CMR readers to patient clinical data. The main
concern for bias is the small sample size of <100
participants in 18 of the 22 included studies.
All studies were performed at PH referral centers
and are therefore at risk for referral bias. The
TABLE 1 Characteristics of Included Studies
Study (Ref. #), Year Country Design
Study
Period Size
Female
(%) Age, yrs
mPAP
(mm Hg) IPAH CTD CHD
Other
PAH
Other
PH
Follow-up
(months) Death
Clinical
Events
Abe et al. (12), 2019 Japan CC 2008–2018 65 88 56  15 34  11 54 11 42 (13–86) 9 (14)
Badagliacca et al. (13),
2016
Italy PCS 2011–2013 74 59 55  13 48  13 74 18 (2–33) 31 (42)
Bredfelt et al. (14),
2018
Sweden RCS 2003–2015 75 71 57  19 45  11 33 33 9 28 29 (39) 7 (9)
Brewis et al. (15), 2016 U.K. CC 2004–2014 140 66 55  16 48  13 75 53 1 11 69 61 (44)
Dawes et al. (31), 2018* U.K. CC 2004–2013 256 44 65  17 43  16 57 31 168 48 (24–68) 34 (39)
de Siqueira et al. (16),
2016*
U.S. CC 2003–2013 93 74 52  12 40  15 23 25 22 23 24 (6–52) 25 (36)
Freed et al. (12), 2012 U.S. PCS 2009–2010 58 74 53  14 49  16 24 20 14 10  6 6 (10) 13 (22)
Gan et al. (18), 2007 Holland CC 2001–2005 70 79 50  15 53 14 49 16 5 48 18 (26)
Grapsa et al. (32), 2020 U.K. PCS NR 30 80 47  5 NR 30 24 (17–24) 8 (26)
Jose et al. (30), 2020* U.S. RCS 2013–2019 38 68 51  17 45  15 18 20 20 (11–35) 4 (11)
Kang et al. (19), 2013 South
Korea
PCS 2009–2010 30 74 45  13 51  23 19 2 7 2 17  7 1 (3) 6 (20)
Knight et al. (20), 2015 U.K. CC 2012–2013 40 75 50  5 46  13 12 20 8 20  8 1 (3) 8 (20)
Leng et al. (21), 2019 China CC 2015–2018 80 79 37  15 56  22 21 10 40 9 24 (2–57) 6 (8) 8 (10)
Li et al. (22), 2017 China PCS 2010–2013 41 71 29  9 61  16 41 27 (21–41) 7 (17) 10 (24)
Mouratoglou et al. (23),
2018
Greece PCS NR 36 78 51  14 NR 12 7 9 2 6 20 (4-37) 0 14 (39)
Sato et al. (24), 2015 Japan PCS 2009–2013 68 76 55  22 37  11 10 17 4 37 24 (9-34) 10 (15) 6 (9)
Simpson et al. (25),
2019
U.S. PCS 2007–2014 64 91 57  11 NR 22 42 50 (29–66) 30 (46)
Swift et al. (26), 2017 U.K. RCS 2008–2015 576 54 57  16 48  13 260 195 63 58 42 (17–142) 221
(38)
van de Veerdonk et al.
(27), 2011
Holland PCS 2002–2007 110 76 53  15 49  16 73 20 17 59 (30–74) 30 (27) 2 (2)
van Wolferen et al.
(28), 2007
Holland PCS 1999–2005 64 73 43  13 56  13 64 32  16 19 (30)
Wang et al. (33), 2020 China CC 2013–2018 100 70 37  14 62  22 33 8 58 1 15 (7–27) 9 (9) 21 (21)
Yamada et al. (29),
2012
Japan RCS 2003–2010 41 71 39  14 51  14 41 44  25 32 (78)
Values are median (range), n (%), mean  SD, or n, unless otherwise indicated. *Only patients with pulmonary arterial hypertension (PAH) were included in the analysis.
CC ¼ case-control; CHD ¼ congenital heart disease; CTD ¼ connective tissue disease; IPAH ¼ idiopathic pulmonary arterial hypertension; mPAP ¼ mean pulmonary artery pressure; NR ¼ not reported;
PCS ¼ prospective case series; PAH ¼ pulmonary arterial hypertension; PH ¼ pulmonary hypertension; RCS ¼ retrospective case series; U.K. ¼ United Kingdom; U.S. ¼ United States.
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FIGURE 1 Pooled Baseline CMR Characteristics
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detailed results of the quality assessment are
described in Supplemental Appendix 4, including a
QUIPS (Quality in Prognostic Studies) risk of bias
figure.
Meta-analyses of CMR indices. Clinical worsening was
analyzed separately to mortality in a subgroup anal-
ysis. In 10 studies, providing data exclusively on
mortality, 459 deaths (36%) in 1,282 participants
occurred over a mean follow-up of 54  5 months (8
deaths per 100 patient-years). The hazard ratios of the
meta-analysis are presented in Table 2. A drop of 1%
in RVEF increased the risk of death by 2.2%. A
decrease of 1 ml/m2 in left ventricular (LV) end-
systolic volume index or LV end-diastolic volume
index (LVEDVI) increased the risk of death by 2.1%
and 2.3%, respectively. An increase in RV volumes,
right ventricular end-systolic volume index (RVESVI)
or right ventricular end-diastolic volume index
(RVEDVI), by 1 ml/m2 increased the risk of mortality
by 0.9% and 1%. The forest plots for RV and LV
function and mass are shown in Figure 2 and forests
plots for RV and LV volume measurements in
Figure 3.
In 12 studies, providing data on clinical worsening,
218 (33%) events occurred in 656 participants over a
mean follow-up of 22  4 months (18 clinical
worsening events per 100 patient-years). The com-
posite outcome of clinical worsening included hos-
pitalization for heart failure (42%), escalation to
prostacyclin treatment (18%), deterioration in World
Health Organization functional class (3%), a reduction
in exercise capacity (2%), need for lung trans-
plantation (2%), nonspecified aforementioned
nonfatal event (14%), and all-cause death (19%). RV
but not LV volumetric and functional measurements
predicted clinical worsening. A 1% deterioration in
RVEF was associated with a 4.9% increase in the risk
of clinical worsening, and a 1 ml/m2 increase in
RVESVI or RVEDVI was associated with an increase of
clinical worsening of 1.3% and 0.7%, respectively.
HETEROGENEITY. There was high statistical hetero-
geneity in the overall result of RVEF, LV mass index,
and LVEDVI, and moderate heterogeneity in LV end-
systolic volume index, RVEDVI, and RVSVI. A meta-
regression model of the logHR of these variables
showed no evidence of a linear relationship with age,
male sex, 6-min walking test, or right heart cathe-
terization parameters (Supplemental Appendix 5).
There may, however, be sources of heterogeneity that
could not be assessed in a meta-regression analysis
where not enough data were available. There were
differences in the types of clinical worsening events
TABLE 2 Results of Meta-analyses of Univariate Hazard Ratios for CMR Measurements
CMR Measurement
Overall Meta-analysis Mortality Outcome Clinical Worsening
HR (95% CI) Studies (n) HR (95% CI) Studies (n) HR (95% CI) Studies (n)
RVEF 0.963 (0.951–0.976) 21 (1,868) 0.978 (0.964–0.993) 9 (1,212) 0.951 (0.935–0.966) 12 (656)
RVEDVI 1.008 (1.006–1.011) 19 (1,808) 1.010 (1.006–1.013) 8 (1,182) 1.007 (1.002–1.013) 11 (626)
RVESVI 1.011 (1.008–1.014) 17 (1,676) 1.009 (1.005–1.012) 7 (1,118) 1.013 (1.008–1.019) 10 (558)
RVSVI 0.987 (0.975–1.000) 13 (1,328) 0.975 (0.948–1.004) 5 (944) 0.993 (0.979–1.007) 8 (384)
LVEF 0.991 (0.983–0.999) 16 (1,625) 0.994 (0.985–1.003) 8 (1,182) 0.981 (0.963–0.999) 8 (443)
LVEDVI 0.983 (0.973–0.994) 16 (1,625) 0.977 (0.965–0.989) 8 (1,182) 0.989 (0.972–1.008) 8 (443)
LVESVI 0.989 (0.977–1.001) 14 (1,421) 0.979 (0.966–0.992) 6 (978) 0.998 (0.980–1.016) 8 (443)
LVSVI 0.973 (0.959–0.987) 11 (1,344) 0.970 (0.959–0.981) 7 (1,118) 0.982 (0.936–1.031) 4 (226)
RVMI 1.010 (1.001–1.018) 11 (1,284) 1.006 (0.999–1.013) 6 (1,007) 1.018 (0.994–1.041) 5 (277)
LVMI 1.009 (0.997–1.021) 12 (1,421) 1.005 (0.994–1.016) 7 (1,094) 1.022 (0.991–1.053) 5 (327)
CI ¼ confidence interval; CMR ¼ cardiac magnetic resonance; HR ¼ hazard ratio; LVEDVI ¼ left ventricular end-diastolic volume index; LVEF ¼ left ventricular ejection fraction; LVESVI ¼ left ventricular end-
systolic volume index; LVMI ¼ left ventricular mass index; LVSVI ¼ left ventricular stroke volume index; RVEDVI ¼ right ventricular end-diastolic volume index; RVEF ¼ right ventricular ejection fraction;
RVMI ¼ right ventricular mass index; RVESVI ¼ right ventricular end-systolic volume index; RVSVI ¼ right ventricular stroke volume index.
FIGURE 1 Continued
The included studies had homogeneous mean baseline cardiac magnetic resonance (CMR) measurements as shown by the overlapping
confidence intervals, with relatively more heterogeneity in right ventricular mass and volumes. The overall pooled mean CMR measurements
show moderately impaired right ventricular function and volumes at baseline and indicate a relatively advanced disease. LVEDVI ¼ left
ventricular end-diastolic volume index; LVEF ¼ left ventricular ejection fraction; LVESVI ¼ left ventricular end-systolic volume index;
LVMI ¼ left ventricular mass index; RVEDVI ¼ right ventricular end-diastolic volume index; RVEF ¼ right ventricular ejection fraction;
RVMI ¼ right ventricular mass index; RVESVI ¼ right ventricular end-systolic volume index.
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used as endpoints, length of follow-up, and the sub-
groups of PAH studied. Other causes of heterogeneity
may include variation in baseline CMR measurements
(Figure 1), disease severity, and treatment status.
There is also geographic variation: 11 studies were
from European centers, 4 from the United States, and
7 from Japan, South Korea, and China.
PUBLICATION BIAS. Unpublished data from previ-
ously published studies were obtained to reduce the
risk of publication bias (Supplemental Appendix 6).
All funnel plots showed asymmetry because of 3
outlier studies with extreme results (Supplemental
Appendix 7). The results of Dawes 2018 (31), Knight
2015 (20), and Van Wolferen 2007 (28) had very
large effect sizes and SEs. Removing these studies
in a sensitivity analysis did not significantly change
the results of the meta-analyses and restored sym-
metry in the funnel plots. The possible source of
the asymmetry in the funnel plots could therefore
be poor methodological designs (due to small sam-
ple size) or inadequate analysis that led to the
inflated effects in those studies. However, it may
FIGURE 2 Meta-Analyses of RV and LV Function and Mass
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0.98 [0.95, 1.00]
0.98 [0.96, 1.00]
0.76 [0.53, 1.09]
1.04 [0.98, 1.11]
0.98 [0.95, 1.01]
0.99 [0.98, 0.99]
0.94 [0.90, 0.98]
0.52 [0.21, 1.29]
0.98 [0.96, 0.99]
0.85 [0.79, 0.92]
0.97 [0.93, 1.00]
0.95 [0.92, 0.98]
0.93 [0.85, 1.00]
0.96 [0.91, 1.01]
0.42 [0.19, 0.93]
0.95 [0.91, 0.99]
0.91 [0.79, 1.04]
0.96 [0.91, 1.01]
0.95 [0.91, 0.99]
0.96 [0.93, 0.98]
0.97 [0.92, 1.02]
0.95 [0.94, 0.97]
2.3%
6.9%
7.2%
2.2%
4.1%
0.0%
5.4%
0.9%
4.1%
5.4%
7.9%
4.2%
50.7%
8.3%
1.2%
17.8%
0.1%
2.6%
45.5%
4.5%
0.0%
80.0%
0.99 [0.92, 1.07]
1.00 [0.97, 1.03]
0.99 [0.97, 1.01]
1.01 [0.72, 1.43]
1.01 [0.96, 1.06]
0.99 [0.98, 1.01]
1.00 [0.96, 1.04]
0.65 [0.26, 1.62]
0.99 [0.98, 1.00]
4.6%
4.0%
0.6%
0.0%
2.3%
1.2%
5.9%
1.3%
20.0%
0.99 [0.95, 1.03]
0.99 [0.95, 1.03]
0.91 [0.82, 1.01]
0.78 [0.39, 1.56]
0.96 [0.91, 1.01]
0.97 [0.90, 1.05]
0.99 [0.96, 1.03]
0.95 [0.88, 1.02]
0.98 [0.96, 1.00]
5.0%
19.4%
0.1%
18.6%
31.4%
0.0%
74.6%
1.01 [0.97, 1.05]
1.00 [0.99, 1.01]
1.12 [0.82, 1.53]
1.02 [1.01, 1.04]
1.OO [1.00, 1.01]
0.79 [0.30, 2.08]
1.01 [1.00, 1.01]
9.0%
7.1%
3.6%
4.6%
1.0%
25.4%
0.99 [0.97, 1.02]
1.03 [1.00, 1.06]
1.03 [0.99, 1.08]
1.04 [1.00, 1.08]
0.96 [0.88, 1.05]
1.02 [0.99, 1.04]
5.9%
13.1%
11.5%
12.9%
16.5%
3.2%
0.0%
63.1%
1.01 [0.97, 1.05]
0.99 [0.97, 1.01]
0.99 [0.97, 1.01]
1.02 [1.00, 1.04]
1.01 [1.00, 1.02]
1.03 [0.97, 1.09]
0.59 [0.27, 1.29]
1.00 [0.99, 1.02]
7.5%
5.8%
4.5%
14.5%
4.6%
36.9%
The meta-analyses of right ventricular (RV) and left ventricular (LV) function and mass showed that RVEF and RVMI are significant prognostic markers. RVEF could
predict clinical worsening separate from mortality, whereas RVMI is a nonspecific prognostic marker. Unpublished data are indicated by (þ). CI ¼ confidence interval;
other abbreviations as in Figure 1.
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FIGURE 3 Meta-Analyses of RV And LV Volume Measurements
Study or Subgroup
Mortality
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RVEDVI (per 1 ml)
Hazard Ratio, Random, 95% CIWeight
Abe 2019 5.6%
6.4%
6.4%
0.0%
2.1%
15.4%
3.5%
0.0%
39.4%
Bredfelt 2018
Brewis 2016
Dawes 2018
Simpson 2019
Swift 2017
Van de Veerdonk 2011
Van Wolferen 2007
Heterogeneity: I2 = 36%, Overall efect: P = 0.01
Subtotal (95% CI)
1.01 [1.00, 1.02]
1.01 [1.00, 1.02]
1.01 [1.00, 1.02]
1.28 [0.93, 1.76]
1.01 [0.99, 1.03]
1.00 [1.00, 1.01]
1.01 [1.00, 1.03]
4.20 [1.31, 13.47]
1.01 [1.00, 1.01]
Study or Subgroup
Mortality
LVEDVI (per 1 ml)
Hazard Ratio, Random, 95% CIWeight
Abe 2019
Bredfelt 2018
Brewis 2016
Dawes 2018
Simpson 2019
Swift 2017
Van de Veerdonk 2011
Van Wolferen 2007
Heterogeneity: I2 = 41%, Overall efect: P = 0.0002
Heterogeneity: I2 = 66%, Overall efect: P = 0.25
Heterogeneity: I2 = 26%, Overall efect: P < 0.00001
Heterogeneity: I2 = 32%
Overall efect: P < 0.00001
Subtotal (95% CI)
Badagliacca 2016
de Siqueira 2016
Freed 2012
Jose 2019
Knight 2015
Leng 2019
Li 2017
Mouratoglou 2018
Sato 2015
Wang 2020
Yamada 2012
Subtotal (95% Cl)
Total (95% Cl)
5.1%
9.8%
6.4%
1.1%
0.0%
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1.9%
7.4%
7.4%
13.1%
2.1%
60.6%
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1.00 [1.00, 1.01]
1.01 [1.00, 1.02]
1.02 [0.99, 1.05]
1.45 [0.78, 2.70]
1.01 [1.00, 1.02]
1.01 [0.99, 1.03]
1.01 [1.00, 1.02]
1.01 [1.00, 1.02]
1.01 [1.00, 1.01]
1.02 [1.00, 1.04]
0.85 0.9 1 1.1 1.2
1.01 [1.01, 1.01]
1.01 [1.01, 1.01]
Lower Increases Event Higher Increases Event
Heterogeneity: I2 = 58%
Overall efect: P = 0.0002
Total (95% Cl) 0.98 [0.97, 0.99]
Clinical Worsening
de Siqueira 2016
Freed 2012
Jose 2019
Knight 2015
Leng 2019
Mouratoglou 2018
Wang 2020
Yamada 2012
Subtotal (95% Cl)
2.7%
8.6%
8.8%
0.1%
9.3%
13.4%
0.0%
5.8%
48.8%
0.98 [0.92, 1.03]
0.99 [0.96, 1.01]
0.97 [0.95, 0.99]
1.23 [0.92, 1.63]
0.98 [0.96, 1.00]
0.98 [0.97, 0.99]
0.96 [0.93, 0.99]
0.31 [0.13, 0.74]
0.98 [0.96, 0.99]
10.8%
6.1%
1.7%
0.0%
9.3%
6.4%
10.3%
6.6%
51.2%
1.00 [0.98, 1.02]
0.96 [0.93, 0.99]
0.94 [0.87, 1.01]
0.34 [0.12, 0.96]
0.99 [0.97, 1.01]
1.00 [0.97, 1.03]
0.98 [0.96, 0.99]
1.03 [1.00, 1.06]
0.99 [0.97, 1.01]
0.85 0.9 1 1.1 1.2
Lower Increases Event Higher Increases Event
Study or Subgroup
Mortality
Clinical Worsening
RVESVI (per 1 ml)
Hazard Ratio, Random, 95% CIWeight
Abe 2019
Bredfelt 2018
Brewis 2016
Dawes 2018
Simpson 2019
Swift 2017
Van de Veerdonk 2011
Heterogeneity: I2 = 0%, Overall efect: P < 0.00001
Subtotal (95% CI)
Study or Subgroup
Mortality
LVESVI (per 1 ml)
Hazard Ratio, Random, 95% CIWeight
Abe 2019
Bredfelt 2018
Dawes 2018
Simpson 2019
Swift 2017
Van de Veerdonk 2011
Heterogeneity: I2 = 0%, Overall efect: P = 0.002
Heterogeneity: I2 = 34%, Overall efect: P = 0.80
Heterogeneity: I2 = 46%, Overall efect: P < 0.00001
Heterogeneity: I2 = 26%
Overall efect: P < 0.00001
Subtotal (95% CI)
Badagliacca 2016
de Siqueira 2016
Freed 2012
Jose 2019
Knight 2015
Leng 2019
Li 2017
Mouratoglou 2018
Wang 2020
Yamada 2012
Subtotal (95% Cl)
Total (95% Cl)
0.85 0.9 1 1.1 1.2
1.01 [1.01, 1.01]
Lower Increases Event Higher Increases Event
Heterogeneity: I2 = 27%
Overall efect: P = 0.07
Total (95% Cl) 0.99 [0.98, 1.00]
Clinical Worsening
de Siqueira 2016
Freed 2012
Jose 2019
Knight 2015
Leng 2019
Mouratoglou 2018
Wang 2020
Yamada 2012
Subtotal (95% Cl)
0.85 0.9 1 1.1 1.2
Lower Increases Event Higher Increases Event
4.9%
7.2%
7.2%
0.0%
7.2%
15.9%
4.9%
47.4%
1.02 [1.00, 1.03]
1.01 [1.00, 1.02]
1.01 [1.00, 1.02]
1.25 [0.92, 1.70]
1.01 [1.00, 1.02]
1.01 [1.00, 1.01]
1.01 [1.00, 1.03]
1.01 [1.01, 1.01]
5.7%
9.7%
7.2%
1.5%
0.0%
7.2%
2.1%
3.1%
13.6%
2.3%
52.6%
1.03 [1.02, 1.04]
1.01 [1.00, 1.01]
1.01 [1.00, 1.02]
1.02 [1.00, 1.05]
1.65 [0.89, 3.06]
1.01 [1.00, 1.02]
1.02 [0.99, 1.04]
1.02 [1.00, 1.04]
1.01 [1.00, 1.01]
1.02 [1.00, 1.04]
1.01 [1.01, 1.02]
12.1%
1.8%
0.2%
4.6%
19.9%
3.9%
42.4%
0.98 [0.89, 1.07]
0.99 [0.96, 1.02]
1.18 [0.86, 1.62]
0.96 [0.91, 1.01]
0.98 [0.96, 1.00]
0.94 [0.89, 1.00]
0.98 [0.97, 0.99]
9.1%
6.8%
1.9%
0.0%
7.1%
10.8%
14.3%
7.5%
57.6%
1.01 [0.98, 1.04]
0.98 [0.94, 1.02]
1.01 [0.92, 1.10]
0.73 [0.36, 1.48]
1.00 [0.96, 1.04]
1.00 [0.97, 1.03]
0.97 [0.95, 1.00]
1.04 [1.00, 1.08]
1.00 [0.98, 1.02]
Study or Subgroup
Mortality
Clinical Worsening
RV SVI (per 1 ml)
Hazard Ratio, Random, 95% CIWeight
Abe 2019
Bredfelt 2018
Brewis 2016
Dawes 2018
Swift 2017
Heterogeneity: I2 = 70%, Overall efect: P = 0.09
Subtotal (95% CI)
Study or Subgroup
Mortality
LV SVI (per 1 ml)
Hazard Ratio, Random, 95% CIWeight
Abe 2019
Bredfelt 2018
Dawes 2018
Simpson 2019
Swift 2017
Van de Veerdonk 2011
Heterogeneity: I2 = 0%, Overall efect: P < 0.00001
Heterogeneity: I2 = 50%, Overall efect: P = 0.46
Heterogeneity: I2 = 9%, Overall efect: P = 0.32
Heterogeneity: I2 = 43%
Overall efect: P = 0.05
Subtotal (95% CI)
de Siqueira 2016
Freed 2012
Jose 2019
Knight 2015
Leng 2019
Li 2017
Mouratoglou 2018
Yamada 2012
Subtotal (95% Cl)
Total (95% Cl)
0.85 0.9 1 1.1 1.2
0.99 [0.98, 1.00]
Lower Increases Event Higher Increases Event
Heterogeneity: I2 = 18%
Overall efect: P = 0.0002
Total (95% Cl) 0.97 [0.96, 0.99]
Clinical Worsening
de Siqueira 2016
Knight 2015
Leng 2019
Mouratoglou 2018
Subtotal (95% Cl)
0.85 0.9 1 1.1 1.2
Lower Increases Event Higher Increases Event
Brewis 2016
13.6%
0.0%
3.9%
6.2%
23.8%
3.0%
9.8%
10.5%
0.2%
22.4%
45.8%
0.92 [0.86, 0.98]
1.00 [0.96, 1.03]
0.95 [0.92, 0.98]
1.13 [0.82, 1.56]
1.00 [0.99, 1.00]
0.98 [0.95, 1.00]
11.0%
15.0%
2.0%
0.0%
6.9%
1.4%
10.8%
7.1%
54.2%
1.00 [0.97, 1.02]
0.98 [0.96, 1.00]
0.95 [0.87, 1.04]
0.56 [0.25, 1.25]
0.99 [0.95, 1.03]
0.96 [0.86, 1.07]
1.02 [0.99, 1.04]
1.01 [0.97, 1.05]
1.00 [0.98, 1.01]
2.8%
12.2%
15.3%
0.3%
13.2%
25.6%
6.8%
76.2%
0.97 [0.89, 1.05]
0.98 [0.94, 1.01]
0.96 [0.93, 0.98]
1.25 [0.95, 1.65]
0.97 [0.94, 1.00]
0.98 [0.96, 0.99]
0.94 [0.90, 0.99]
0.97 [0.96, 0.98]
1.00 [0.97, 1.03]
0.32 [0.13, 0.79]
0.97 [0.92, 1.02]
0.99 [0.92, 1.06]
0.98 [0.94, 1.03]
RV and LV volumes are significant prognostic markers. A decrease in RV volumes can predict mortality and clinical worsening, whereas an increase in LV volumes
indicates an increased risk for death only. Unpublished data are indicated by (þ). LVSVI ¼ left ventricular stroke volume index; RVSVI ¼ right ventricular stroke volume
index; other abbreviations as in Figures 1 and 2.
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also indicate that some studies with extreme nega-
tive results have not been published.
DISCUSSION
To the best of our knowledge, this paper is the largest
meta-analysis of CMR imaging in patients with PAH
and the first to report on clinical worsening in addi-
tion to mortality. We have confirmed that CMR im-
aging is a powerful prognostic marker in a large
cohort of patients from multiple institutions, across
several continents and using different imaging plat-
forms. In addition, we have shown that CMR imaging
predicts clinical worsening in patients with PAH. Our
findings highlight the clinical utility of CMR imaging
and support further evaluation of this modality as a
clinically meaningful trial endpoint for the assess-
ment of new therapies for PAH (Central Illustration,
Table 3).
Clinical worsening as a composite endpoint has
been shown to predict mortality (34) and has
established itself as a primary efficacy endpoint in
trials of PAH therapies (7,35). Although heart failure
and all-cause mortality are included in all PAH trials
using a composite clinical worsening endpoint, these
trials vary in their inclusion and definition of pro-
gression markers, such as change in exercise toler-
ance or functional capacity (36), and they may use
different thresholds to define a meaningful change
(37). Nonetheless, study designs using time to clin-
ical worsening have been increasingly adopted to
evaluate PAH therapies. However, such studies
require large numbers of participants and a pro-
longed period of follow-up, usually lasting for
several years. As a consequence and given recent
events such as the coronavirus disease 2019
pandemic, there has been a focus on considering
clinical trial endpoints, which allow the impact of
candidate therapies to be assessed over a shorter
period and using an endpoint that correlates with
clinically meaningful events.
In this meta-analysis, we have shown for the first
time in a large cohort of patients that CMR-derived
RV volumetric and functional metrics but not LV
measurements predict clinical worsening. This infor-
mation should be helpful to regulatory authorities
CENTRAL ILLUSTRATION Cardiac Magnetic Resonance Imaging for Prediction of Clinical
Worsening and Mortality in Pulmonary Arterial Hypertension
68%
52
1,938
per 1% decrease 2.2% increase 4.9% increaseRVEF
0.9% increase 1.3% increaseper 1 ml/m2 increaseRVESVI
2.1% increase Not signiicantper 1 ml/m2 decreaseLVESVI
3% increase Not signiicantper 1 ml/m2 decreaseLVSVI
1% increase 0.7% increaseper 1 ml/m2 increaseRVEDVI
2.3% increase Not signiicantper 1 ml/m2 decreaseLVEDVI
RVEF
RVESVI
LVESVI
LVSVI
Hazard Ratios
1.041.021.000.980.960.94 1.041.021.000.980.960.94
RVEDVI
LVEDVI
Results Increment
Mortality Risk
(Over 54 Months)
Clinical Worsening
(Over 22 Months)
22
studies
Cochrane
Medline
Embase
Web of
Science
Mortality Clinical Worsening
Years old
Alabed, S. et al. J Am Coll Cardiol Img. 2020;-(-):-–-.
Pooled results for mortality and clinical worsening are presented in the forest plots and described in the table underneath for various factors.
The literature search details and demographic characteristics of the meta-analysis cohort are shown on the left. LVEDVI ¼ left ventricular
end-diastolic volume index; LVESVI¼ left ventricular end-systolic volume index; LVSVI¼ left ventricular stroke volume index; RVEDVI ¼ right
ventricular end-diastolic volume index; RVEF ¼ right ventricular ejection fraction; RVESVI ¼ right ventricular end-systolic volume index.
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who are keen to ensure that proposed trial endpoints
have clinical relevance. In addition, this meta-
analysis confirms the prognostic value of CMR met-
rics in a substantial cohort of patients, which has
allowed an assessment of the impact of change on
specific metrics concerning clinical worsening,
including mortality. A 1% decrease in RVEF is asso-
ciated with a 4.9% increase in the risk of clinical
worsening and a 2.2% increase in the risk of death. In
addition, a 1 ml/m2 increase in RV volumes is associ-
ated with a 0.9% to 1% increase in the risk of mor-
tality and a 0.7% to 1.3% increase in the risk of clinical
worsening. Although this incremental change in RV
volumes is smaller than the 2.1% to 2.3% associated
with a decrease in LV volume, the overall risk of
mortality is more linked to RV volume, previously
highlighted in large cohort studies (26,38). Specif-
ically, the increase in RV volume due to dilation in
response to an increase in afterload is substantially
larger than the change in LV volume, occurring as a
consequence of ventricular interaction (39), particu-
larly in advanced disease in PAH when uncoupling of
the right ventricle and its load occurs (40).
This meta-analysis has shown that an increased RV
mass has prognostic value but does not predict clin-
ical worsening. In PAH, an increase in RV mass and
RV hypertrophy is likely to represent an appropriate
adaptive response to an increase in afterload (41). In a
CMR study in which patients were monitored over 5
years, RV wall thickness was not associated with
increased mortality in patients who were judged to be
clinically stable (39). Moreover, a disproportionate
increase in right ventricular mass index (RVMI)
compared with RVEDV indicates concentric hyper-
trophy and is associated with a favorable outcome in
IPAH (13). Eccentric hypertrophy with a dispropor-
tionate increase in RVEDV compared with RVMI is
considered a maladaptive response to increased
afterload and is associated with a poor outcome
(13,41). In IPAH, therefore, caution should be exer-
cised when using mass measurements in isolation
because they give incomplete information on RV
adaptation. Further study of the relationship between
RV mass and volume would be helpful. In CTD-PAH,
in which the natural history of the disease is
different, RVMI and ventricular mass index (VMI)
seem to have greater prognostic value than RV func-
tion or volumes (17,30,31,51). A 10% increase in RVMI
and VMI was associated with an increased risk of
death of 10% to 15% (25). A VMI $0.7 was associated
with 35% mortality at 1 year and 67% mortality at 2
years (42). RV hypertrophy in CTD-PAH may be an
early prognostic marker for mortality rather than just
an adaptive response to PH (25). This finding em-
phasizes the importance of considering the clinical
context when using tools to assess prognosis.
Several additional CMR measurements have been
shown in small studies to have prognostic value, and
additional data are provided in Supplemental Appen-
dix 8. These analyses include right atrial volume and
area, pulmonary artery relative area change and
distensibility, and the ratio of stroke volume/RV end-
systolic volume. Additional CMR prognostic markers
that were not assessed in the meta-analysis include
myocardial strain analysis, myocardial T1 mapping,
and late gadolinium enhancement. The small number
of studies reporting these markers, or the absence of
Cox regression analysis, prevented a meaningful
pooling of their results. Strain analysis using feature
tracking seems to be a promising prognostic marker
TABLE 3 Summary of Findings
Review question What are the CMR predictors for clinical worsening and mortality in patients with PAH?
Population 1,938 participants, including 68% female subjects, aged 52  15 yrs.
Participants had more advanced disease and intermediate to high risk for 1-yr mortality
Follow-up 22  4 months for clinical worsening and 54  5 months for mortality
Setting Tertiary pulmonary hypertension referral centers
Studies Case series and case-control studies
Quality of evidence Some concerns for bias due to small sample sizes, retrospective design, lack of blinding in most studies and non-consecutive inclusion in
half of the studies.
Results Increment Clinical Worsening (Over 22 Months) Mortality Risk (Over 54 Months)
RVEF per 1% decrease 4.9% increase 2.2% increase
RVESVI per 1 ml/m2 increase 1.3% increase 0.9% increase
RVEDVI per 1 ml/m2 increase 0.7% increase 1% increase
LVEDVI per 1 ml/m2 decrease Not significant 2.3% increase
LVESVI per 1 ml/m2 decrease Not significant 2.1% increase
LVSVI per 1 ml/m2 decrease Not significant 3% increase
Abbreviations as in Tables 1 and 2.
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(16,21,43); however, it needs to be evaluated further in
a more extensive survival study. Late gadolinium
enhancement (17,44,45) and T1 mapping (46) have an
unclear additive prognostic value in PAH.
The meta-analysis is based on a population likely
to have disease at the more severe end of the spec-
trum. The results may therefore not be generalizable
to patients with more modest disease, in which age
and comorbidity may have more of an impact on
prognosis. A recently published, large well-designed
study has shown that CMR could be used to estab-
lish thresholds for mortality risk in PAH (38). This
study showed that CMR metrics can be used to
improve risk stratification when incorporated into
the French Registry approach or REVEAL (Registry to
Evaluate Early and Long-Term Pulmonary Arterial
Hypertension Disease Management) risk scores
(47,48). In the study by Lewis et al. (38), an
RVEF <37%, an RVESVI of >54 ml/m2, and LVEDVI
of <52 ml/m2 were associated with a high risk of
mortality. In this meta-analysis, the pooled RVEF was
37%, RVESVI 63 ml/m2, and LVEDVI 57 ml/m2. All
included studies used the current guideline criteria
of an mPAP threshold $25 mm Hg. A new threshold
of >20 mm Hg with a pulmonary vascular
resistance $3 Wood units has recently been proposed
as a hemodynamic definition for PAH, being 2 SDs
above the normal threshold (49). There remains a
lack of evidence therefore regarding the prognostic
value of CMR in patients who have modest PAH and
those with mPAP >20 mm Hg, in whom other factors
may be more of a driver to clinical worsening and
mortality.
STUDY LIMITATIONS. An extensive systematic liter-
ature search was performed, and a pre-published
protocol was followed. However, a potential limita-
tion of this study is that inclusion was assessed by a
single investigator. Any doubt regarding study se-
lection was discussed with another investigator,
however. This meta-analysis contains previously un-
published data for participants included in previously
published studies. However, this approach has
allowed improved data completeness and additional
analysis. The included studies including supple-
mental data are indicated by (þ) in Figures 2 and 3.
The unpublished univariate hazard ratios are pro-
vided in Supplemental Appendix 5. Patients in this
study included a cohort with a predominantly inter-
mediate and high risk of 1-year mortality and likely
represent a cohort with more severe disease.
Although the results of the meta-analysis suggest that
CMR imaging, as performed in expert centers,
strongly associates with outcomes, some caution is
warranted in its application in less-experienced cen-
ters given the limited existence of multicenter
studies. In some instances, heterogeneity is high, and
greater caution in interpretation is therefore indi-
cated. Finally, only limited data are provided on the
potential of CMR metrics such as myocardial strain
analysis, right atrial size, pulmonary artery wall
stiffness, and four-dimensional flow parameters and
the application of artificial intelligence approaches to
large imaging datasets, which may add clinical value.
CONCLUSIONS
This meta-analysis is the first to study the role of CMR
in the prediction of clinical worsening in PAH. We
have shown that CMR can predict clinical worsening,
in addition to confirming its prognostic role, in a large
cohort of patients with PAH. This study provides a
strong rationale for considering CMR as a clinical trial
endpoint.
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